Compounds > 4-amino-1,8-naphthalimide
Page last updated: 2024-10-21

4-amino-1,8-naphthalimide and Leukemia

4-amino-1,8-naphthalimide has been researched along with Leukemia in 1 studies

4-amino-1,8-naphthalimide: inhibits ADP-ribosylation; sometimes abreviated as 4-AN;

Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Pogrebniak, A1
Schemainda, I1
Pelka-Fleischer, R1
Nüssler, V1
Hasmann, M1

Other Studies

1 other study available for 4-amino-1,8-naphthalimide and Leukemia

ArticleYear
Poly ADP-ribose polymerase (PARP) inhibitors transiently protect leukemia cells from alkylating agent induced cell death by three different effects.
    European journal of medical research, 2003, Oct-22, Volume: 8, Issue:10

    Topics: 1-Naphthylamine; Adenosine Triphosphate; Alkylating Agents; Apoptosis; Benzamides; Cell Death; Cell

2003